Correction: Phase 1 First-in-Human Dose Escalation and Dose Expansion Study of KLS-1 (64Zinc Aspartate) in Patients With Cancer and Neurodegenerative Diseases.

Authors

Jesus A Perez
Javier J Lopez
Claudia C Torres Badillo
Jaya Gill, Department of Translational Neurosciences, Pacific Neuroscience Institute and Saint John's Cancer Institute at Providence Saint John's Health Center, Santa Monica, USA.Follow
Santosh Kesari, Department of Translational Neurosciences, Pacific Neuroscience Institute and Saint John's Cancer Institute at Providence Saint John's Health Center, Santa Monica, USA.Follow
Peter Novak
Max Temnikov
Roman Byshovets
Oleg Bychkov

Document Type

Article

Publication Date

10-1-2022

Publication Title

Cureus

Keywords

california; pni; santa monica

Abstract

[This corrects the article DOI: 10.7759/cureus.29921.].

Clinical Institute

Cancer

Clinical Institute

Neurosciences (Brain & Spine)

Department

Oncology

Department

Neurosciences

Recommended Citation

Perez, Jesus A; Lopez, Javier J; Torres Badillo, Claudia C; Gill, Jaya; Kesari, Santosh; Novak, Peter; Temnikov, Max; Byshovets, Roman; and Bychkov, Oleg, "Correction: Phase 1 First-in-Human Dose Escalation and Dose Expansion Study of KLS-1 (64Zinc Aspartate) in Patients With Cancer and Neurodegenerative Diseases." (2022). Articles, Abstracts, and Reports. 6709.
https://digitalcommons.providence.org/publications/6709